1	The	_	DT	_	_	2	NMOD	_	_
2	amount	_	NN	_	_	13	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	blood	_	NN	_	_	3	PMOD	_	_
5	surgical	_	JJ	_	_	6	NMOD	_	_
6	patients	_	NNS	_	_	7	SBJ	_	_
7	can	_	MD	_	_	4	NMOD	_	_
8	donate	_	VB	_	_	7	VC	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	store	_	VB	_	_	9	CONJ	_	_
11	before	_	IN	_	_	8	TMP	_	_
12	surgery	_	NN	_	_	11	PMOD	_	_
13	can	_	MD	_	_	0	ROOT	_	_
14	be	_	VB	_	_	13	VC	_	_
15	increased	_	VBN	_	_	14	VC	_	_
16	by	_	IN	_	_	15	LGS	_	_
17	the	_	DT	_	_	21	NMOD	_	_
18	new	_	JJ	_	_	21	NMOD	_	_
19	genetically	_	RB	_	_	20	AMOD	_	_
20	engineered	_	VBN	_	_	21	NMOD	_	_
21	drug	_	NN	_	_	16	PMOD	_	_
22	,	_	,	_	_	21	P	_	_
23	EPO	_	NNP	_	_	21	APPO	_	_
24	.	_	.	_	_	13	P	_	_

1	EPO	_	NNP	_	_	6	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	or	_	CC	_	_	1	COORD	_	_
4	erythropoietin	_	NN	_	_	3	CONJ	_	_
5	,	_	,	_	_	1	P	_	_
6	is	_	VBZ	_	_	0	ROOT	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	protein	_	NN	_	_	6	PRD	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	human	_	JJ	_	_	11	NMOD	_	_
11	body	_	NN	_	_	12	SBJ	_	_
12	makes	_	VBZ	_	_	8	NMOD	_	_
13	to	_	TO	_	_	12	PRP	_	_
14	stimulate	_	VB	_	_	13	IM	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	growth	_	NN	_	_	14	OBJ	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	red	_	JJ	_	_	20	NMOD	_	_
19	blood	_	NN	_	_	20	NMOD	_	_
20	cells	_	NNS	_	_	17	PMOD	_	_
21	.	_	.	_	_	6	P	_	_

1	A	_	DT	_	_	4	NMOD	_	_
2	genetically	_	RB	_	_	3	AMOD	_	_
3	engineered	_	VBN	_	_	4	NMOD	_	_
4	version	_	NN	_	_	20	SBJ	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	8	NMOD	_	_
7	human	_	JJ	_	_	8	NMOD	_	_
8	protein	_	NN	_	_	5	PMOD	_	_
9	developed	_	VBN	_	_	4	APPO	_	_
10	by	_	IN	_	_	9	LGS	_	_
11	Amgen	_	NNP	_	_	10	PMOD	_	_
12	Corp.	_	NNP	_	_	11	POSTHON	_	_
13	of	_	IN	_	_	11	NMOD	_	_
14	Thousand	_	NNP	_	_	15	NAME	_	_
15	Oaks	_	NNP	_	_	13	PMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	Calif.	_	NNP	_	_	15	APPO	_	_
18	,	_	,	_	_	15	P	_	_
19	recently	_	RB	_	_	20	TMP	_	_
20	has	_	VBZ	_	_	0	ROOT	_	_
21	been	_	VBN	_	_	20	VC	_	_
22	marketed	_	VBN	_	_	21	VC	_	_
23	by	_	IN	_	_	22	LGS	_	_
24	the	_	DT	_	_	27	NMOD	_	_
25	Ortho	_	NNP	_	_	27	NMOD	_	_
26	Pharmaceuticals	_	NNP	_	_	27	NMOD	_	_
27	division	_	NN	_	_	23	PMOD	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	Johnson	_	NNP	_	_	28	PMOD	_	_
30	&	_	CC	_	_	29	COORD	_	_
31	Johnson	_	NNP	_	_	30	CONJ	_	_
32	.	_	.	_	_	20	P	_	_

1	A	_	DT	_	_	3	NMOD	_	_
2	competing	_	VBG	_	_	3	NMOD	_	_
3	version	_	NN	_	_	6	SBJ	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	EPO	_	NNP	_	_	4	PMOD	_	_
6	is	_	VBZ	_	_	0	ROOT	_	_
7	being	_	VBG	_	_	6	VC	_	_
8	developed	_	VBN	_	_	7	VC	_	_
9	by	_	IN	_	_	8	LGS	_	_
10	Genetics	_	NNP	_	_	11	NAME	_	_
11	Institute	_	NNP	_	_	9	PMOD	_	_
12	Inc.	_	NNP	_	_	11	POSTHON	_	_
13	in	_	IN	_	_	11	LOC	_	_
14	Cambridge	_	NNP	_	_	13	PMOD	_	_
15	,	_	,	_	_	14	P	_	_
16	Mass	_	NNP	_	_	14	APPO	_	_
17	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	drug	_	NN	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	being	_	VBG	_	_	3	VC	_	_
5	used	_	VBN	_	_	4	VC	_	_
6	primarily	_	RB	_	_	5	ADV	_	_
7	to	_	TO	_	_	5	OPRD	_	_
8	treat	_	VB	_	_	7	IM	_	_
9	anemias	_	NNS	_	_	8	OBJ	_	_
10	.	_	.	_	_	3	P	_	_

1	A	_	DT	_	_	3	NMOD	_	_
2	new	_	JJ	_	_	3	NMOD	_	_
3	experiment	_	NN	_	_	16	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	reported	_	VBN	_	_	3	APPO	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	this	_	DT	_	_	8	NMOD	_	_
8	week	_	NN	_	_	12	NMOD	_	_
9	's	_	POS	_	_	8	SUFFIX	_	_
10	New	_	NNP	_	_	12	NAME	_	_
11	England	_	NNP	_	_	12	NAME	_	_
12	Journal	_	NNP	_	_	6	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	Medicine	_	NNP	_	_	13	PMOD	_	_
15	,	_	,	_	_	3	P	_	_
16	involved	_	VBD	_	_	0	ROOT	_	_
17	giving	_	VBG	_	_	16	OPRD	_	_
18	injections	_	NNS	_	_	17	OBJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	Amgen	_	NNP	_	_	22	NMOD	_	_
21	's	_	POS	_	_	20	SUFFIX	_	_
22	EPO	_	NNP	_	_	19	PMOD	_	_
23	to	_	TO	_	_	17	DTV	_	_
24	23	_	CD	_	_	25	NMOD	_	_
25	patients	_	NNS	_	_	23	PMOD	_	_
26	who	_	WP	_	_	27	SBJ	_	_
27	wanted	_	VBD	_	_	25	NMOD	_	_
28	to	_	TO	_	_	27	OPRD	_	_
29	store	_	VB	_	_	28	IM	_	_
30	units	_	NNS	_	_	29	OBJ	_	_
31	of	_	IN	_	_	30	NMOD	_	_
32	their	_	PRP$	_	_	34	NMOD	_	_
33	own	_	JJ	_	_	34	NMOD	_	_
34	blood	_	NN	_	_	31	PMOD	_	_
35	.	_	.	_	_	16	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	patients	_	NNS	_	_	3	SBJ	_	_
3	began	_	VBD	_	_	0	ROOT	_	_
4	receiving	_	VBG	_	_	3	OPRD	_	_
5	EPO	_	NNP	_	_	6	NMOD	_	_
6	injections	_	NNS	_	_	4	OBJ	_	_
7	about	_	IN	_	_	8	DEP	_	_
8	a	_	DT	_	_	9	NMOD	_	_
9	month	_	NN	_	_	10	ADV	_	_
10	before	_	IN	_	_	4	TMP	_	_
11	their	_	PRP$	_	_	13	NMOD	_	_
12	scheduled	_	VBN	_	_	13	NMOD	_	_
13	surgery	_	NN	_	_	10	PMOD	_	_
14	.	_	.	_	_	3	P	_	_

1	They	_	PRP	_	_	3	SBJ	_	_
2	then	_	RB	_	_	3	TMP	_	_
3	began	_	VBD	_	_	0	ROOT	_	_
4	donating	_	VBG	_	_	3	OPRD	_	_
5	blood	_	NN	_	_	4	OBJ	_	_
6	twice	_	RB	_	_	8	NMOD	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	week	_	NN	_	_	4	TMP	_	_
9	,	_	,	_	_	4	P	_	_
10	receiving	_	VBG	_	_	4	ADV	_	_
11	an	_	DT	_	_	13	NMOD	_	_
12	EPO	_	NNP	_	_	13	NMOD	_	_
13	injection	_	NN	_	_	10	OBJ	_	_
14	each	_	DT	_	_	15	NMOD	_	_
15	time	_	NN	_	_	10	TMP	_	_
16	.	_	.	_	_	3	P	_	_

1	If	_	IN	_	_	12	ADV	_	_
2	tests	_	NNS	_	_	3	SBJ	_	_
3	indicated	_	VBD	_	_	1	SUB	_	_
4	a	_	DT	_	_	6	NMOD	_	_
5	low	_	JJ	_	_	6	NMOD	_	_
6	number	_	NN	_	_	3	OBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	red	_	JJ	_	_	9	NMOD	_	_
9	cells	_	NNS	_	_	7	PMOD	_	_
10	,	_	,	_	_	12	P	_	_
11	blood	_	NN	_	_	12	SBJ	_	_
12	was	_	VBD	_	_	0	ROOT	_	_
13	n't	_	RB	_	_	12	ADV	_	_
14	taken	_	VBN	_	_	12	VC	_	_
15	.	_	.	_	_	12	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	EPO-treated	_	JJ	_	_	3	NMOD	_	_
3	patients	_	NNS	_	_	4	SBJ	_	_
4	donated	_	VBD	_	_	0	ROOT	_	_
5	an	_	DT	_	_	6	NMOD	_	_
6	average	_	NN	_	_	4	OBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	5.4	_	CD	_	_	9	NMOD	_	_
9	units	_	NNS	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	blood	_	NN	_	_	10	PMOD	_	_
12	each	_	DT	_	_	6	ADV	_	_
13	compared	_	VBN	_	_	4	ADV	_	_
14	with	_	IN	_	_	13	PMOD	_	_
15	only	_	RB	_	_	17	NMOD	_	_
16	4.1	_	CD	_	_	15	DEP	_	_
17	units	_	NNS	_	_	14	PMOD	_	_
18	donated	_	VBN	_	_	17	APPO	_	_
19	by	_	IN	_	_	18	LGS	_	_
20	a	_	DT	_	_	22	NMOD	_	_
21	similar	_	JJ	_	_	22	NMOD	_	_
22	group	_	NN	_	_	19	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	surgical	_	JJ	_	_	25	NMOD	_	_
25	patients	_	NNS	_	_	23	PMOD	_	_
26	who	_	WP	_	_	27	SBJ	_	_
27	received	_	VBD	_	_	25	NMOD	_	_
28	a	_	DT	_	_	30	NMOD	_	_
29	placebo	_	NN	_	_	30	NMOD	_	_
30	injection	_	NN	_	_	27	OBJ	_	_
31	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	volume	_	NN	_	_	11	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	red	_	JJ	_	_	5	NMOD	_	_
5	cells	_	NNS	_	_	3	PMOD	_	_
6	donated	_	VBN	_	_	5	APPO	_	_
7	by	_	IN	_	_	6	LGS	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	EPO-treated	_	JJ	_	_	10	NMOD	_	_
10	patients	_	NNS	_	_	7	PMOD	_	_
11	was	_	VBD	_	_	29	OBJ	_	_
12	41	_	CD	_	_	13	NMOD	_	_
13	%	_	NN	_	_	14	AMOD	_	_
14	higher	_	JJR	_	_	11	PRD	_	_
15	per	_	IN	_	_	11	ADV	_	_
16	donor	_	NN	_	_	15	PMOD	_	_
17	,	_	,	_	_	29	P	_	_
18	the	_	DT	_	_	20	NMOD	_	_
19	research	_	NN	_	_	20	NMOD	_	_
20	team	_	NN	_	_	29	SBJ	_	_
21	representing	_	VBG	_	_	20	APPO	_	_
22	a	_	DT	_	_	23	NMOD	_	_
23	number	_	NN	_	_	21	OBJ	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	hospitals	_	NNS	_	_	24	PMOD	_	_
26	and	_	CC	_	_	25	COORD	_	_
27	blood	_	NN	_	_	28	NMOD	_	_
28	banks	_	NNS	_	_	26	CONJ	_	_
29	reported	_	VBD	_	_	0	ROOT	_	_
30	.	_	.	_	_	29	P	_	_

